2014
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez E, Thompson E, Anderson S, Asmann Y, Kalari K, Eckel-Passow J, Dueck A, Tenner K, Jen J, Fan J, Geiger X, McCullough A, Chen B, Zschunke M, Jenkins R, Sledge G, Winer E, Gralow J, Reinholz M, Ballman K. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. Journal Of Clinical Oncology 2014, 32: 509-509. DOI: 10.1200/jco.2014.32.15_suppl.509.Peer-Reviewed Original Research
2005
Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
Citron M, Berry D, Cirrincione C, Livingston R, Gradishar W, Perez E, Muss H, Norton L, Winer E, Hudis C. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Journal Of Clinical Oncology 2005, 23: 620-620. DOI: 10.1200/jco.2005.23.16_suppl.620.Peer-Reviewed Original Research